3-year, Open-Label Study Evaluating Safety, Tolerability, and Efficacy of Lorecivivint in Knee Osteoarthritis

Summary

This study is designed as a 3-year, multicenter, open-label study evaluating the safety, tolerability, and efficacy of intra-articular (IA) Lorecivivint (LOR) in subjects with osteoarthritis of the knee in a real-world setting.

Timeline

Start

2021-07-15

Primary completion

2021-12-13

Completion

2021-12-13

Outcome

Outcome not reported

Stopped (Business): “Study was terminated by Sponsor based on a business decision not due to safety. The study report was finalized without any statistical analysis.”

Drugs

Indications